Head to Head Analysis: Quantum Biopharma (NASDAQ:QNTM) & Veracyte (NASDAQ:VCYT)

Quantum Biopharma (NASDAQ:QNTM) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Quantum Biopharma and Veracyte”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17 million	($8.25)	-0.42
Veracyte	$517.15 million	6.95	$66.35 million	$1.41	31.69

Veracyte has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quantum Biopharma and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Veracyte	20.37%	9.26%	8.61%

Volatility & Risk

Quantum Biopharma has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Quantum Biopharma and Veracyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1	0	0	0	1.00
Veracyte	1	2	6	2	2.82

Veracyte has a consensus price target of $54.33, indicating a potential upside of 21.61%. Given Veracyte’s stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than Quantum Biopharma.

Institutional and Insider Ownership

1.2% of Quantum Biopharma shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Veracyte beats Quantum Biopharma on 12 of the 14 factors compared between the two stocks.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.